The diminished AKT phosphorylation we observed in thyroid carcinoma cells, beside possible direct effects, may also be the result of receptor tyrosine kinase inhibition by sorafenib and has recently been described in prostate cancer cells [60]. The gene discussed is AKT1; the disease is Familial prostate cancer.